COPE
Volume 2, Number 4 (Nov 2014)                   Res Mol Med (RMM) 2014, 2(4): 3-11 | Back to browse issues page




DOI: 10.18869/acadpub.rmm.2.4.3

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tari K, Yarahmadi R, Tabatabaei A, Saba F, Abroun S, Atashi A et al . Myeloproliferative disorders and its associated mutations. Res Mol Med (RMM). 2014; 2 (4) :3-11
URL: http://rmm.mazums.ac.ir/article-1-100-en.html

Abstract:   (2006 Views)

Myeloproliferative Neoplasm (MPN) are a clonal disorder in hematopoietic stem cells (HSC). MPN is categorized to 8 subclasses, including chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocytopenia (ET), primary myelofibrosis (PMF), systematic mastositosis (SM), chronic eosinophilic leukemia (CEL), chronic neutrophilic leukemia (CNL), and unclassified myelofibrosis disorders (UMPN). It usually occurs in 5th to 7th decade of life. However, CNL and ET have been observed in children. A lot of mutations have been identified in these disorders that Jak2V617F is the most important mutation. Moreover, several somatic mutations other than JAK2V617F in MPN patients have been reported. Such mutations include MPL, TET2, ASXL1, IDH1, IDH2, CBL, LNK, IKZF, and EZH2 from precursor stem cells. The role of mutations mentioned is not clear in pathogenesis of this disease. Hence, in this study, mutations in different stages of myeloproliferative disorders have been reviewed.

Full-Text [PDF 680 kb]   (953 Downloads)    
Type of Study: review | Subject: Hematology & Oncology
Received: 2014/09/17 | Accepted: 2014/10/24 | Published: 2014/10/24

Add your comments about this article : Your username or email:
Write the security code in the box

Send email to the article author


© 2015 All Rights Reserved | Research in Molecular Medicine

Designed & Developed by : Yektaweb